Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
While progress has been made in understanding the mechanism of cancer and in the development of innovative therapeutic agents, despite this, the attrition rates between target discovery and drug marketing approval remains high, especially in oncology. It is hypothesized that one of the main reason underlying this undesirable statistics is believed to be the lack of predictive power of the model systems used in the preclinical setting. Tumor heterogeneity is a challenge in cancer research and drug development, and It is now demonstrated that patient-derived xenograft (PDX) cancer models should clearly help to better mimic the situation of the human cancer pathologies.
In this presentation, we will discuss how PDX and PDX-derived models should be incorporated into different stages of the drug discovery process taking example of Drug Positioning in Breast Cancer with relevant human projection.
Join Oncodesign and HitGen studying the paradigm of novel approaches in the discovery of new drugs in Oncology across selected examples. It will be a unique opportunity to interactively discuss, debate and answer questions about how oncology drug discovery works today, and how to better apply the concept of personalized medicine to your oncology research within a consortium of experts in their own field from hit finding to pharmacology.
Key learning objectives
A succinct introduction to the application of DNA-encoded library technology via the recently published example Naa50. There will be a focus on the mechanics of DEL, including an analysis of the advantages, and challenges, of the technology. The narrative will be directed towards those considering DEL technology for identifying ligands for their target of interest. A succinct introduction to the PDX models. There will be a focus on PDX-derived models incorporated into different stages of the drug discovery process.
Discover our speaker Olivier Duchamp
Olivier Duchamp, Head of In vivo sciences, Oncodesign Service Business Unit
Olivier Duchamp is the head of the In Vivo Sciences Department at Oncodesign. He was at the founding of the company and for the last 23 years, contributed largely to its development and innovation in preclinical models and pharmaco-imaging. He holds a Bachelor degree from the University of Lyon (France) and a Master degree in pharmacology and analytical methods from the University of Paris IV (France).
Olivier is also the coordinator of IMODI, (Innovative MODels Initiative) a French consortium dedicated to the development, the characterization and the commercialization of new preclinical models in oncology, including PDX models and humanized mouse models. He is the co-author of several publications about PDX models.
Discover our speaker Barry A. Morgan
Barry A. Morgan, Ph.D. is Chief Scientific Officer for HitGen Inc., where he focuses on developing and applying DNA-encoded chemistry technology to early stage small-molecule drug discovery. Barry has over 40 years of experience in R&D in the Pharmaceutical and Biotechnology industries in the UK, France and the USA. He was Vice President, Molecular Discovery, and Site and Business Head at GlaxoSmithKline, Boston 2007-2012. He was previously Senior Vice President for Chemistry and Discovery Sciences at PRAECIS PHARMACEUTICALS Inc., where he was a primary inventor of DNA Encoded Library (DEL) Technology. Barry has presented invited seminars at over 100 Academic and Industry Symposia in Europe, the USA and China, has authored over 100 publications and posters, and is an inventor on more than 40 patents in the area of drug discovery. He has contributed to over twenty drug development candidates in a range of therapeutic areas, of which more than ten have advanced to clinical study.
Barry has a faculty position at the Institute for Molecular Medicine, University of Texas Health Sciences, Houston TX, where he focuses on collaborations applying DEL technology to novel drug targets in academia, and the economics of drug discovery and development.